Staar Surgicalの空売り状況は、投資家がStaar Surgicalの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Staar Surgical (NASDAQ:STAA) 株価情報, 空売り情報

Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

Mid Cap

News

Movers

CRDO

DJTWW

ENVX

FIZZ

GLBE

GRND

KVYO

STAA

TGLS

先週、これらの中型株は最も優れた業績を発揮しました。あなたのポートフォリオには含まれていますか？

中小株式市場　今週注目の10銘柄

Staar Surgical Co

On January 17, BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000718937/000091957425000375//Archives/edgar/data/718937/000091957425000375/0000919574-25-000375-index.htm">U.S. Securities and Exchange Commission</a> on Friday, LP increased their investment in Staar Surgical by purchasing 29,376 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $630,838.
At Friday morning, Staar Surgical shares are up by 3.0%, trading at $22.51.
<h3>Get to Know Staar Surgical Better</h3>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Key Indicators: Staar Surgical's Financial Health</h3>
Revenue Growth: Staar Surgical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.31%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 77.31%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Staar Surgical exhibits below-average bottom-line performance with a current EPS of 0.2.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.09, Staar Surgical adopts a prudent financial strategy, indicating a balanced approach to debt management.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 49.67 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 3.17 is lower than the industry average, implying a discounted valuation for Staar Surgical's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 28.03 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000718937">Check Out The Full List Of Staar Surgical's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

BROADWOOD PARTNERS LP Takes a Bullish Stance: Acquires $630K In Staar Surgical Stock

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on Staar Surgicalto Hold

It was revealed in a recent SEC filing that BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) made a noteworthy insider purchase on December 19,.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000718937/000091957424007190//Archives/edgar/data/718937/000091957424007190/0000919574-24-007190-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, LP increased their investment in Staar Surgical by purchasing 80,200 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $1,947,539.
As of Thursday morning, Staar Surgical shares are up by 3.34%, currently priced at $25.07.
<h3>Discovering Staar Surgical: A Closer Look</h3>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Financial Insights: Staar Surgical</h3>
Positive Revenue Trend: Examining Staar Surgical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 77.31%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Staar Surgical exhibits below-average bottom-line performance with a current EPS of 0.2.
</li>
</ul>
Debt Management: Staar Surgical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 55.03 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.51 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 31.73 reflects market recognition of Staar Surgical's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000718937">Check Out The Full List Of Staar Surgical's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10% Owner Of Staar Surgical Purchased $1.95M In Stock

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $31 to $28.

Price Target

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $28

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Analyst Color

Biotech

Upgrades

Downgrades

Health Care

General

DXCM

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

TMDX

TNDM

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $41 to $31.

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $31

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold.

Needham Reiterates Hold on Staar Surgical

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.17 by 94.12 percent. The company reported quarterly sales of $88.60 million which beat the analyst consensus estimate of $86.91 million by 1.95 percent. This is a 10.33 percent increase over sales of $80.31 million the same period last year.

Earnings

Earnings Beats

Staar Surgical Q3 2024 Adj EPS $0.33 Beats $0.17 Estimate, Sales $88.60M Beat $86.91M Estimate

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Staar Surgical to report an earnings per share (EPS) of $0.17.
Anticipation surrounds Staar Surgical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.09, leading to a 11.03% increase in the share price on the subsequent day.
Here's a look at Staar Surgical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.24</td>
<td>0.04</td>
<td>0.17</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.15</td>
<td>-0.07</td>
<td>0.16</td>
<td>0.30</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.0%</td>
<td>-12.0%</td>
<td>3.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730214181_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Staar Surgical were trading at $30.69 as of October 28. Over the last 52-week period, shares are down 29.54%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Staar Surgical</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Staar Surgical.
A total of 2 analyst ratings have been received for Staar Surgical, with the consensus rating being Buy. The average one-year price target stands at $42.5, suggesting a potential 38.48% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Establishment Labs Hldgs, RxSight and Bioventus, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Establishment Labs Hldgs is maintaining an Neutral status according to analysts, with an average 1-year price target of $55.6, indicating a potential 81.17% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for RxSight, with an average 1-year price target of $63.14, implying a potential 105.73% upside.</li>
<li>Bioventus received a Buy consensus from analysts, with an average 1-year price target of $13.67, implying a potential 55.46% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Establishment Labs Hldgs, RxSight and Bioventus, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staar Surgical</td>
<td>Buy</td>
<td>7.26%</td>
<td>$78.41M</td>
<td>1.84%</td>
</tr>
<tr>
<td>Establishment Labs Hldgs</td>
<td>Neutral</td>
<td>-9.15%</td>
<td>$28.94M</td>
<td>-33.71%</td>
</tr>
<tr>
<td>RxSight</td>
<td>Buy</td>
<td>67.65%</td>
<td>$24.25M</td>
<td>-2.77%</td>
</tr>
<tr>
<td>Bioventus</td>
<td>Buy</td>
<td>10.32%</td>
<td>$103.64M</td>
<td>-14.89%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Staar Surgical is at the top for Revenue Growth and Gross Profit, while it is at the bottom for Return on Equity among its peers.
<h3>Delving into Staar Surgical's Background</h3>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Key Indicators: Staar Surgical's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 7.26%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's net margin is impressive, surpassing industry averages. With a net margin of 7.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's ROE excels beyond industry benchmarks, reaching 1.84%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Staar Surgical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Staar Surgical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<a href="https://www.benzinga.com/quote/STAA/earnings">To track all earnings releases for Staar Surgical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Staar Surgical's Earnings Expectations

Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.75, along with a high estimate of $53.00 and a low estimate of $37.00. A decline of 7.41% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1726747277_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Staar Surgical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Staar Surgical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>A Deep Dive into Staar Surgical's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 7.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Staar Surgical's net margin excels beyond industry benchmarks, reaching 7.45%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.47%, the company showcases effective utilization of assets.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Staar Surgical

5 analysts have shared their evaluations of Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.2, a high estimate of $53.00, and a low estimate of $37.00. This current average represents a 6.46% decrease from the previous average price target of $47.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1724688030_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Staar Surgical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Staar Surgical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Staar Surgical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Staar Surgical's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Staar Surgical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.26% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.45% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Staar Surgical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.84%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.47%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Staar Surgical's Future

Stifel analyst Thomas Stephan maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and lowers the price target from $50 to $44.

Stifel Maintains Buy on Staar Surgical, Lowers Price Target to $44

Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.25, along with a high estimate of $53.00 and a low estimate of $37.00. Experiencing a 4.49% decline, the current average is now lower than the previous average price target of $46.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1723122068_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Staar Surgical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Staar Surgical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Staar Surgical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Staar Surgical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Financial Milestones: Staar Surgical's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Staar Surgical's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.21%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.32% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Staar Surgical's ROE stands out, surpassing industry averages. With an impressive ROE of -0.86%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Staar Surgical Through 4 Analysts

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $43 to $41.

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $41

Guidance

STAAR Surgical Raises FY24 Outlook For Net Sales From $335M - $340M To $340M - $345M, Est $339.974M

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 50 percent. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $99.005 million which beat the analyst consensus estimate of $95.202 million by 3.99 percent. This is a 7.26 percent increase over sales of $92.306 million the same period last year.

Staar Surgical Q2 2024 GAAP EPS $0.15 Beats $0.10 Estimate, Sales $99.005M Beat $95.202M Estimate

BTIG analyst Ryan Zimmerman maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and raises the price target from $46 to $53.

BTIG Maintains Buy on Staar Surgical, Raises Price Target to $53

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $44.2, a high estimate of $55.00, and a low estimate of $37.00. Experiencing a 2.86% decline, the current average is now lower than the previous average price target of $45.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1721052059_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Staar Surgical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$37.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Staar Surgical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Staar Surgical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Financial Insights: Staar Surgical</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 5.21%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Staar Surgical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.68% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Staar Surgical Through The Eyes Of 5 Analysts

Oppenheimer analyst Steven Lichtman maintained a Hold rating on Staar Surgical (STAA – Research Report) today. The company's shares closed yesterda...

Oppenheimer Reaffirms Their Hold Rating on Staar Surgical (STAA)

In a report released yesterday, Thomas Stephan from Stifel Nicolaus maintained a Buy rating on Staar Surgical (STAA – Research Report), with a pric...

Staar Surgical (STAA) Receives a Buy from Stifel Nicolaus

BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) yesterday and set a price target of $49.00. The comp...

BTIG Reaffirms Their Buy Rating on Staar Surgical (STAA)

STAAR Surgical: Turning A Blind Eye

Morgan Stanley analyst Patrick Wood lowered the firm's price target on Staar Surgical (STAA) to $23 from $27 and keeps an Underweight rating on the...

Staar Surgical price target lowered to $23 from $27 at Morgan Stanley

BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $39.00. The company'...

Staar Surgical (STAA) Receives a Buy from BTIG

BTIG lowered the firm's price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of a broader research no...

Staar Surgical price target lowered to $39 from $49 at BTIG

Canaccord Genuity analyst John Young CFA has maintained their neutral stance on STAA stock, giving a Hold rating yesterday. John Young CFA has give...

Staar Surgical: Hold Rating Amid Competitive Pressures and Strategic Initiatives

Stifel Nicolaus analyst Thomas Stephan has maintained their bullish stance on STAA stock, giving a Buy rating on January 7. Thomas Stephan's rating...

Comments

Staar Surgical

空売り

Staar Surgical (NASDAQ:STAA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル